Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib 70 mg twice daily versus 140 mg once daily in advanced Philadelphia chromosome-positive leukemia after imatinib resistance or intolerance
2005-001169-32Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dasatinib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Efficacy. Started May 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2005-001169-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001169-32.